Angioimmunoblastic T-Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma (AILT), aka immunoblastic lymphadenopathy, is an aggressive cancer that originates in the T-cells. It accounts for 1% of all Non-Hodgkin’s Lymphomas (NHL) and is found mostly in the elderly. Males have a higher incidence than females.
"Angio" is a term that refers to the blood vessels. This cancer is marked by the presence of abnormal blood vessels in affected body parts. AILT typically affects the lymph nodes, skin, liver, spleen, and bone marrow.
Immunoblasts are immature immune cells. AILT originates in immature T-cells that circulate in the blood.
Diagnosis and Staging
Most patients present with typical lymphoma symptoms, such as fever, night sweats, chills, swollen lymph nodes, and weight loss. Some patients will also have a skin rash. In the later stages, patients may be anemic (low red blood cell and/or hemoglobin count) or have other blood abnormalities, so they’ll experience fatigue as a result.
A lymph node biopsy is used to diagnose the disease, and other follow-up tests like CT scans, PET scans, X-rays, and bone marrow biopsies are done to stage the cancer. Due to the rarity of this disease, concrete staging information is not available.
Treatment
Treament usually begins with steroids to help with inflammation and rashes. After steroid treatment, the CHOP regimen of chemotherapy is usually administered.
In cases of relapse, bone marrow transplants are usually tried.
Related Article
Clinical Trials
Cancer Patients have more options through clinical studies. Follow this link to learn more and find a clinical study opportunity near you.
Dive Deeper
Resources
- Non-Hodgkin's Lymphoma - US National Cancer Institute
- Non-Hodgkin's Lymphoma for Health Professionals - US National Cancer Institute
Non-Hodgkin's Lymphoma Information Pages:
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
